CD11b/Integrin Alpha M/ITGAM Drug Discovery Landscape & Assay Solutions
- By admin
- 03 Sep 2026
- Comments
Market Intelligence, Clinical Progress, and High-Purity Reagents for Myeloid-Targeted Immunotherapy and Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CD11b drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD11b/ITGAM ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View CD11b Products |
| Gene Delivery | CD11b Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View CD11b Products |
| Benchmark Ab | Anti-CD11b (Sequence of Clinical/Validation Clones) Recombinant positive control. |
View CD11b Products |
| Validator | CD11b siRNA Set For knockdown verification. |
View CD11b Products |
| Related Target A | ITGB2 (CD18) Essential heterodimerization partner to form functional Mac-1 (AMB2) integrin. |
View ITGB2 Products |
| Related Target B | ICAM1 (CD54) Primary endothelial ligand involved in CD11b-mediated cell adhesion and trafficking. |
View ICAM1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformation-dependent binding (Active vs. Inactive states) | HEK293 expressed recombinant CD11b preserving native glycosylation and structural plasticity. |
| Heterodimeric complex validation (CD11b/CD18) | Lentiviral vectors optimized for dual-transduction to build stable, functional cell lines. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live CD11b R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD11b therapeutics is intensifying, with major players shifting focus from traditional immunosuppression to myeloid-derived suppressor cell (MDSC) reprogramming in the tumor microenvironment. While early efforts focused on CD11b antagonists to block inflammatory cell recruitment, the next wave of R&D targets CD11b activation. Small-molecule agonists are being utilized to stabilize the active conformation of CD11b, which inhibits the pro-tumorigenic immunosuppressive functions of myeloid cells and promotes an anti-tumor phenotype.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Agonists | Adastra Pharmaceuticals, GB Life Sciences | Solid Tumors (Colorectal, Pancreatic) | Conformational shift assays (Need high-purity CD11b/CD18 heterodimers) |
| Monoclonal Antibodies | Academic Institutions, Bio-Pharma | Ischemic Stroke, Lupus Nephritis | Epitope mapping & ligand blocking (Need recombinant ICAM1 & CD11b ECD) |
| Cell-Based Screeners | Immunology Research Labs | Inflammatory Bowel Disease (IBD) | Stable cell lines expressing functional Mac-1 (Need CD11b/ITGB2 Lentivirus) |